The startup operates a bio convergence platform that utilizes photosynthetic microalgae for the autonomic culture of animal tissue, eliminating the need for bioreactors in the differentiation, scaffolding, and hypertrophy processes. This approach significantly lowers costs and enhances scalability in cultured meat production.
Funding
$850K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Cultured meat production faces significant cost and scalability challenges due to the reliance on expensive bioreactors for cell differentiation, scaffolding, and hypertrophy. Traditional methods also require substantial media usage and efficient removal of toxic by-products.
Solution
CultivO2 offers a bio convergence platform that utilizes photosynthetic microalgae for autonomic animal tissue culture, eliminating the need for traditional bioreactors. The platform creates a symbiotic ecosystem where microalgae continuously produce oxygen, growth factors, and glucose while consuming toxic by-products like ammonia and lactate. This co-culture system supports the growth of animal cells on an edible tissue scaffold, ensuring efficient nutrient exchange and dramatically reducing media usage. The setup also allows for easy separation of algae and animal cell tissue, offering flexibility and control over the final product.
Target Audience
CultivO2 targets companies in the food and FoodTec industry involved in or seeking to integrate and develop sustainable meat products.
Features
- Multi-scaffold co-culture platform creating a symbiotic ecosystem for animal cell growth.
- Photosynthetic microalgae scaffold continuously producing oxygen, growth factors, and glucose.
- Edible animal cell tissue scaffold supporting animal cell growth within the optimized environment.
- Reduced media usage and lower cost of biomass production due to efficient nutrient exchange.
- Easy separation of algae and animal cell tissue at later stages of production.
- PCT patent-pending technology.